IL1B and Insulin resistance: Given that the antidiabetic action of anakinra mainly relies on the preservation of beta cell mass and function, this drug may be a good therapeutic option to counteract IL-1β-driven beta cell dysfunction and to halt or slow down the progressive decline in insulin secretion occurring over time in RA patients with comorbid T2D and insulin resistance.